<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149695_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152633</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHO2011US07887</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20110504</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130123</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2011US07887</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Mary</reportergivename>
			<reporterfamilyname>Waybill</reporterfamilyname>
			<reporterstreet>205 S Front Street 
Brady 8. Harrisburg, 
PA 17105</reporterstreet>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
			<sponsorstudynumb>CRAD001AUS92</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<primarysource>
			<reportergivename>Paula</reportergivename>
			<reporterfamilyname>Kratzer</reporterfamilyname>
			<reporterstreet>205 S Front Street 
Brady 8. Harrisburg, 
PA 17105</reporterstreet>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>REL</patientinitial>
			<patientinvestigationnumb>15</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19480605</patientbirthdate>
			<patientweight>137.9</patientweight>
			<patientheight>184</patientheight>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Kidney transplant rejection</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110502</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Drug dose omission</patientepisodename>
				<patientmedicalcomment>By patient</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Oedema peripheral</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Haemodialysis</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110503</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal transplant</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110412</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cardiac failure congestive</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Nephropathy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Renal dysfunction</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Kidney dysfunction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal impairment</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Acute tubular necrosis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Acute tubular necrosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal tubular necrosis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20120519</reactionenddate>
				<reactionduration>384</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>4</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Lack of efficacy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110505</testdate>
				<testname>Biopsy</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110425</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Blood culture</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood potassium</testname>
				<testresult>4.4</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood potassium</testname>
				<testresult>4.4</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood potassium</testname>
				<testresult>6.2</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood potassium</testname>
				<testresult>6.2</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Culture urine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Ultrasound kidney</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood albumin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Protein total increased</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood chloride</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood calcium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood pressure</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CERTICAN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>21-560</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.75</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>805</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>29.6299992</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>0.75 mg, Q12H</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110413</drugstartdate>
				<drugstartperiod>20</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20110509</drugenddate>
				<drugtreatmentduration>27</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PROGRAF</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>3</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>805</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>48</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>3 mg, Q12H</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110425</drugstartdate>
				<drugstartperiod>8</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20110502</drugenddate>
				<drugtreatmentduration>8</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>3</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TACROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PROGRAF</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugcumulativedosagenumb>48</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>UNK</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110502</drugstartdate>
				<drugstartperiod>8</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>3</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TACROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISONE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>15 mg, UNK</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110427</drugstartdate>
				<drugstartperiod>6</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20110502</drugenddate>
				<drugtreatmentduration>6</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ZAROXOLYN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METOLAZONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>THYMOGLOBULINE                          /FRA/</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ANTITHYMOCYTE IMMUNOGLOBULIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2011US07887, is an initial report received on 04 May 2011, from clinical study CRAD001AUS92. This 62-year-old male subject [centre number 547, subject number 15] was enrolled in a12 month, multi-centre, randomized, open-label non-inferiority study comparing the safety and efficacy of concentration-controlled Everolimus with low dose tacrolimus to CellCept (mycophenolate mofetil) with standard dose tacrolimus in de novo renal transplant recipients.  

The subject's medical history included congestive heart failure, diabetes mellitus, renal disease including nephrolithiasis and hypertension. The subject underwent kidney transplant on 12 Apr 2011. Concomitant medications included Zaroxolyn and Thymoglobulin. The subject started RAD001, at a dose of 0.75mg Q12h, on 13 Apr 2011. He started treatment with Prograf, at a dose of 3mg Q12h, on 25 Apr 2011 and started treatment with prednisone, at a dose of 15mg QD, on 27 Apr 2011. On 28 Apr 2011, the subject had blood urea nitrogen 30 (unknown units), serum creatinine 2.0 (unknown units), hemoglobin 9.5 (unknown units), albumin 2.8 (unknown units), serum total protein 6.0 (unknown units), electrolytes including sodium 148 (unknown units), potassium 4.4 (unknown units), chlorine 113 (unknown units), calcium 22.5 (unknown units), blood pressure 152/84 (unknown units). On 29 Apr 2011, the subject missed his morning medications. On 02 May 2011, 20 days after initiation of RAD001, 8 days after initiation of Prograf and 6 days after initiation of prednisone, a transplanted kidney ultrasound showed abnormal resisting of the arcuate arteries. Creatinine on this date was 6.9. Blood and urine cultures were performed, the results were pending. On this date Prograf was dose increased. An ultrasound on this date showed abnormal resisting of the arcuate arteries and was suspicious for rejection. The investigator reported this as renal dysfunction. On an unknown date, the subject had decreased urinary output. The subject was hospitalized on an unknown date due to the event and treatment with Solu-Medrol and Cefepime was started. On 03 May 2011 creatinine was 8.2 and potassium was 6.2mmol/l (normal = 3.3 - 5.1mmol/l). The subject was treated with hemodialysis and given a dose of Thymoglobulin. On 05 May 2011, the renal biopsy was performed, which showed acute tubular necrosis. On 09 May 2011, the study drug was discontinued due to the event (took last dose on 09 May 2011). The subject received immunosuppressants, antimicrobials and diuretics unspecified on an unknown date. The investigator indicated that the events were due to lack of efficacy stating that the subject may not have been immunosuppressed enough especially in light of missed medication dosing. The subject's condition was recovered with sequelae as of 19 May 2012 for the event of acute tubular necrosis. On the same day, the subject was discharged from the hospital. At the time of reporting, the subject's condition was persisting for the events of renal dysfunction and lack of efficacy. The events were considered serious (hospitalization) by the investigator.

The investigator suspected a relationship between the events and RAD001, Prograf and prednisone.

Follow-up DR report received on 22 Aug 2012: The investigator confirmed that, the event renal dysfunction was serious adverse event (previously coded as consequence on the subject's medical history page).

Follow-up report received on 01 Oct 2012: Updated lab data, treatment medication, new diagnosis (acute tubular necrosis) with onset, seriousness, causality and outcome.

Follow-up checklist for renal impairment or failure received on 23 Jan 2013: Updated medical history, laboratory information, treatment medications.</narrativeincludeclinical>
				<sendercomment>Serious adverse drug reaction report, (hospitalisation), assessed as expected according to the Investigator's Brochure. Investigator causality is suspected.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
